Please login to the form below
low-income countries
This page shows the latest low-income countries news and features for those working in and with pharma, biotech and healthcare.
UK-India research project trialling easy-to-use UTI test to support fight against AMR
time. Globally, urinary tract infections (UTIs) are the second leading cause of antibiotic consumption, often purchased over the counter in India, one of the highest human antibiotic-using countries in the ... Additionally, the DOSA project aims to
Latest news
-
New WHO initiative to prioritise endemic pathogens for vaccine development
that pose the biggest threat to public health and socio-economic burden, particularly in low- and middle-income countries.
-
LSTM and LifeArc announce partnership and research fund to tackle infectious diseases
The £2.7m fund from LifeArc will support the progression of potential interventions, including diagnostics, treatments and devices, that are appropriately aligned with the deployment and treatment of patients in low- ... and middle-income countries
-
World Health Organization publishes updated essential medicines list
The new Model Lists intends to grant better access to innovative medicines that show major clinical benefits, impacting public health globally without affecting the health budgets of low- and middle-income ... countries conducted milestone trials
-
Gates Foundation and Wellcome to fund late-stage trial of tuberculosis vaccine candidate
Despite being both curable and preventable, the disease continues to affect around ten million people every year, and 1.6 million people died from it in 2021, almost entirely in low ... and middle-income countries.
-
World Health Organization publishes research agenda for antimicrobial resistance
to address AMR, particularly in low-and-middle-income countries. ... G7 countries to support R&D into new antibiotics, but also the remaining gaps in ensuring a robust pipeline of treatments.
More from news
Approximately 1 fully matching, plus 135 partially matching documents found.
Latest Intelligence
-
Tuberculosis – why it remains a major global public health challenge
The disease burden remains greatest in low- and middle-income countries (LMICs), which account for 98% of reported TB cases. ... If results are favourable, the goal is to support policy changes around BCG revaccination in countries with a high TB burden.
-
Congress is in session – how companies are boosting their impact and engagement
A study underscored the point, with analysis of attendances at 112 conferences revealing that only 4% of events were held in Low and Middle Income Countries (LMIC) and only 39% of
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Hard times. According to WHO, fewer than 15% of low-income countries provide comprehensive treatment services for cancer through their public health systems. ... The result? 70% of all cancer deaths in 2020 were in low- and middle-income countries.
-
Meeting healthcare’s rising challenges
which time 80% of older people will be living in low- and middle-income countries. ... disease.’. Allen underscored that potential, particularly in giving a voice to diverse patient groups, and observed: “The impact on rare disease communities will
-
Pharma’s vital role in sustainability and corporate social responsibility
Focusing on such things as access to medicines for low and middle income countries (LMICs) or collaborating with the patient and clinical trials community, although critically important, are no longer sufficient.
More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest appointments
-
Merck KGaA’s Oschmann elected president of IFPMA
Current challenges around non-communicable diseases and infectious diseases demonstrate the need for stronger health systems as well as for local innovative solutions in low and middle income countries,” he said. ... support health goals in these
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Antibiotic resistance: The silent pandemic
Up to 2 billion people, mainly in low- and middle-income countries, lack access to antimicrobials. ... In 2019, it is still estimated that more than 50% of antibiotics in many countries are used inappropriately.
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
The imminent explosion of cell and gene therapies raises issues of affordability for all health systems, not just for low and middle income countries. ... If pricing in low income countries is adopted more widely across the globe, this will kill
-
Case Study: Qualitative research with payers in low and middle income countries
low and middle income countries where patients self-pay for healthcare.
-
Healthcare 2025: what the future holds for pharma
New World Order The growth of populations and income in emerging markets is increasing economic power but also increasing issues of resource sustainability. ... These drive a two tier world of high growth, low individual income countries and low growth,
-
Research Partnership
Published in eyeforpharma February 2016 by Rachel Howard. Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- OPEN Health and Nested Knowledge announce strategic research collaboration to leverage AI technologies for evidence synthesis
- FDA approves two cell-based gene therapies for sickle cell disease
- Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma
- New economic data reveals risk of disincentivising UK life sciences growth
- WHO countries hold seventh INB meeting to prevent global pandemics
- The start of a beautiful friendship
No results were found
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Virtual care – negotiating barriers to adoption offers glimpses of an exciting future
- Digital tools and innovative healthcare promise to address pressing healthcare issues if they can satisfy concerns over access, security and affordability...
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
